Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.06. | NextCell Pharma AB: All Patients Successfully Treated in ProTrans-Young Study | 315 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") announces today that all patients in the ongoing ProTrans-Young clinical trial have now successfully been treated. This milestone marks the completion... ► Artikel lesen | |
02.06. | NEXTCELL PHARMA AB: NextCell Pharma announces outcome of exercise of TO2 and resolves on directed share issues to guarantors | 1 | Cision News | ||
28.05. | NEXTCELL PHARMA AB: NextCell Pharma receives additional declarations of intent regarding exercise of TO2 | 1 | Cision News | ||
28.05. | NEXTCELL PHARMA AB: Angela Vollstedt joins NextCell Pharma's Board of Advisors to Strengthen Scientific and Manufacturing Strategy Ahead of Licensing Discussions | 1 | Cision News | ||
NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
26.05. | NextCell Pharma AB: NextCell Receives US Patent for MSC Prediction Algorithm | 274 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the issuance of a US patent titled "MSC Prediction Algorithm" by the United States Patent and Trademark Office (USPTO). The patent... ► Artikel lesen | |
23.05. | NEXTCELL PHARMA AB: NextCell Pharma receives declarations of intent, subscription undertakings and top guarantees regarding exercise of TO2 | 1 | Cision News | ||
20.05. | NextCell, Fujifilm Irvine Scientific Enter Strategic Pact | 4 | Contract Pharma | ||
20.05. | NextCell Pharma AB: NextCell announces strategic collaboration with Fujifilm Irvine Scientific | 662 | GlobeNewswire (Europe) | NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells... ► Artikel lesen | |
19.05. | NEXTCELL PHARMA AB: Eric Strati Joins NextCell Pharma's Board of Advisors to Support Commercial Strategy for ProTrans | 1 | Cision News | ||
16.05. | NEXTCELL PHARMA AB: The exercise period for NextCell Pharma's warrants of series TO2 begins today | - | Cision News | ||
15.05. | NEXTCELL PHARMA AB: Eight-Year-Old Hugo - Living with Type 1 Diabetes and Participating in the ProTrans Study | 1 | Cision News | ||
07.05. | NEXTCELL PHARMA AB: Study published in Nature Medicine shows promising results in Alzheimer's disease - supports the development of ProTrans at NextCell | 2 | Cision News | ||
25.04. | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 2 2024/2025 | 86 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 - February 28, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
24.04. | NEXTCELL PHARMA AB: NextCell presents detailed analysis of the administrative report from ProTrans-Young | 2 | Cision News | ||
23.04. | NEXTCELL PHARMA AB: NextCell Presents Quarterly Report | 4 | Cision News | ||
15.04. | NextCell Pharma AB: NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward | 109 | GlobeNewswire (Europe) | NextCell Pharma ("the company" or "NextCell") has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the... ► Artikel lesen | |
07.04. | NEXTCELL PHARMA AB: Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young | 1 | Cision News | ||
28.03. | NEXTCELL PHARMA AB: NextCell's CSO Appointed to the Board of ATMP Sweden | 5 | Cision News | ||
19.03. | NEXTCELL PHARMA AB: Recognition for NextCell's CSO from the International Society of Cell and Gene Therapy | 1 | Cision News | ||
13.03. | NextCell Pharma AB: Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv | 371 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient in the older age cohort (12-21 years) of the clinical Phase II study, ProTrans-Young, has now completed their 12-month... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |